OS Therapies Inc

OS Therapies Inc. announced the initial closing of its warrant exercise inducement and exchange offer, raising approximately $7.2 million in gross proceeds. Seven investors exercised or pre-funded warrants to purchase 5,517,253 shares of common stock, in exchange for which the company issued new warrants for the same number of shares. The offer, which allows for a reduced exercise price of $1.30 per share, is expected to yield up to $12.3 million if fully subscribed. The funds will be used for regulatory submissions and commercial preparations for its lead asset, Herlystic™, and for general corporate purposes. The company also noted $7 million in accrued UK R&D tax credits.

OS Therapies Inc. entered into a securities purchase agreement for a private placement of up to $10,000,000 in senior secured convertible promissory notes. The company completed the initial closing of the First Tranche, raising $5,000,000, which included the conversion of a $2,200,000 bridge note. The proceeds are intended for clinical development, regulatory activities, and general corporate purposes.

OS Therapies Inc. has entered into a settlement agreement with Leonite Fund I, LP to resolve disputes stemming from a previously disclosed $10 million senior secured convertible promissory note. Under the terms of the settlement, OS Therapies will pay Leonite $1.9 million in cash and issue 500,000 shares of its common stock by August 7, 2026. Upon closing, the original note, associated commitment shares, and warrant will be terminated, and all security interests will be released, with both parties exchanging mutual releases of claims.

OS Therapies Inc. has terminated its At Market Issuance Sales Agreement with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC, effective July 28, 2026. This agreement, established on August 8, 2025, allowed the company to sell up to $18,000,000 of its common stock. Prior to termination, OS Therapies had sold 282,679 shares, generating approximately $530,162 in gross proceeds, with $17,469,838 remaining unsold. No termination fees were incurred by either party.

OS Therapies Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on September 9, 2026. Stockholders will vote on the election of six directors, the ratification of MaloneBailey, LLP as the independent auditor for 2026, and a significant amendment to the 2023 Incentive Compensation Plan. The proposed amendment seeks to increase the number of shares available for issuance under the plan by 5,000,000, bringing the total to 15,000,000 shares, and eliminate per-person award limitations. The record date for stockholders entitled to vote is July 21, 2026.

OS Therapies Inc. entered into a securities purchase agreement for a senior secured convertible promissory note of up to $10,000,000, along with issuing 275,000 commitment shares and a warrant for up to 1,750,000 shares. The first tranche of $1,600,000 from this note is expected on July 2, 2026. Concurrently, the company secured a $10,000,000 line of credit backed by UK tax credits, with an initial draw of $1,600,000. The proceeds will fund clinical development, regulatory activities, and general corporate purposes, extending the company's cash runway into 2027. Additionally, Dr. Craig Eagle was appointed to the Board of Directors, while Karim Galzahr stepped down.

OS Therapies Inc. reported a net loss of $(10.4) million for the three months ended March 31, 2026, a significant increase from $(3.9) million in the prior year, with basic and diluted loss per share rising to $(0.27). The company used $(4.6) million in cash for operating activities and held $917,552 in cash as of March 31, 2026. Management has raised substantial doubt about the company's ability to continue as a going concern, citing insufficient cash to fund expected Q2-Q4 2026 expenses of approximately $20.0 million, and is actively seeking additional capital.

OS Therapies Inc. announced the European Medicines Agency (EMA) initiated a rolling review for Conditional Marketing Authorization (CMA) of OST-HER2 for osteosarcoma. The company also received Advanced Therapy Medicinal Product (ATMP) designation from the U.K. MHRA and expects European peak sales for OST-HER2 to exceed $300 million, with over $50 million in sales by 2027. Regulatory alignment was achieved with EMA and Australia TGA on key efficacy endpoints and surrogate data, with upcoming meetings with U.S. FDA and U.K. MHRA in Q2 2026. The company also provided updates on its OST-504 and OST-503 pipeline candidates.